Primary efficacy endpoints in phase 3 non-inferiority trials to establish new tuberculosis treatment regimens should only include microbiological outcomes

Affiliations

¹ Institute of Health Informatics, University College London, London, UK; Division of Infection and Immunity, University College London, London, UK.
² Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK. Electronic address: daniel.grint@lshtm.ac.uk.

Free article

Tom A Yates et al. Lancet Microbe. 2025 Jul.

Free article

. 2025 Jul;6(7):101117.

doi: 10.1016/j.lanmic.2025.101117. Epub 2025 Mar 15.

¹ Institute of Health Informatics, University College London, London, UK; Division of Infection and Immunity, University College London, London, UK.
² Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK. Electronic address: daniel.grint@lshtm.ac.uk.

No abstract available

Conflict of interest statement

We declare no competing interests.